Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Abbott Cuts Kaletra Price In 40 Countries

This article was originally published in PharmAsia News

Executive Summary

Abbott announced April 10 that it would cut the price of its HIV therapy Kaletra (lopinavir/ritonavir) in more than 40 developing countries to around $1,000 per patient annually

You may also be interested in...



Generic Sustiva Will Launch In Thailand

Merck’s Thai subsidiary says it will seek meeting to discuss government decision to issue compulsory license for generic treatment.

AIDS Drugs Pricing Plans For Poor Nations May Preclude Legislation

International AIDS Conference is met with announcements from manufacturers of expanded access in developing nations and a renewed call from Sen. Leahy (D-Vt.) for action on his mandatory licensure bill.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Table

View full table

Tags:
Latest Headlines

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

See All
UsernamePublicRestriction

Register

SC066114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By